Sofosbuvir + Velpatasvir Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Sofosbuvir 400 mg + Velpatasvir 100 mg
Reference Brands: Epclusa® (EU & US)
Category:
Hepatitis
Sofosbuvir 400 mg + Velpatasvir 100 mg Tablets (Epclusa® generic) are used to treat all major HCV genotypes. Manufactured under EU-GMP/USFDA compliance, ideal for B2B supply, tenders, and licensing with full CTD and regulatory support.
Sofosbuvir + Velpatasvir is available in Tablet
and strengths such as Sofosbuvir 400 mg + Velpatasvir 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sofosbuvir + Velpatasvir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sofosbuvir + Velpatasvir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sofosbuvir 400 mg + Velpatasvir 100 mg tablets (Epclusa® generic) are oral antivirals indicated for pan-genotypic Hepatitis C treatment. This once-daily fixed-dose combination is effective across all major HCV genotypes and offers high SVR rates. Manufactured under EU-GMP and USFDA-approved facilities, the product is available for B2B supply, tenders, and contract manufacturing. Regulatory support includes CTD dossiers and bioequivalence studies. Widely accepted across EU, US, LATAM, and MENA markets, Sofosbuvir + Velpatasvir is a key addition to antiviral portfolios targeting global Hepatitis C elimination goals.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing